Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Neutral” Rating from Wedbush

Wedbush reaffirmed their neutral rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report published on Friday morning,RTT News reports. The firm currently has a $4.00 price objective on the stock.

A number of other equities research analysts have also issued reports on the company. Guggenheim reduced their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Stock Performance

ZNTL opened at $2.22 on Friday. Zentalis Pharmaceuticals has a one year low of $2.13 and a one year high of $18.07. The company has a market cap of $158.20 million, a price-to-earnings ratio of -0.89 and a beta of 1.86. The business’s fifty day moving average is $3.05 and its two-hundred day moving average is $3.33.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36. On average, analysts predict that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at about $37,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at approximately $37,000. Aigen Investment Management LP acquired a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter worth about $41,000. Capstone Investment Advisors LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $48,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after acquiring an additional 5,333 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.